ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1357 • ACR Convergence 2023

    Systemic Lupus Erythematosus and Assisted Reproductive Technology: A Case Series and Systematic Literature Review

    Erinn Coe1, Emily Petrinec1 and Omer Pamuk2, 1Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, 2Division of Rheumatology, Case Western Reserve University/University Hospitals, Cleveland, OH

    Background/Purpose: Systemic lupus erythematosus (SLE) is one of the most common autoimmune diseases in women of childbearing age and female sex hormones are known to…
  • Abstract Number: 1344 • ACR Convergence 2023

    Efficacy and Safety of JAK Inhibitors in Difficult to Treat Rheumatoid Arthritis in Clinical Practice

    Omar AL TABAA1, Sophie HECQUET2, Marion THOMAS3, Sandrine CARVES1, Alice Combier1, Corinne MICELI4, Olivier Fogel3, Anna Molto3, Yannick ALLANORE5 and Jerome AVOUAC6, 1APHP / Cochin Hospital, Paris, France, 2APHP / Cochin Hospital / Paris University, Paris, France, 3HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, 4Université de Paris Cité, HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, 5Université Paris Cité, Paris, France, 6Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France

    Background/Purpose: Use of JAK inhibitors (JAKi) may be challenged in difficult to treat rheumatoid arthritis (D2TRA) by the multiplicity of previous treatment lines and the…
  • Abstract Number: 1135 • ACR Convergence 2023

    The Prescribing Patterns and Role of TNF-α Inhibitors in Treatment of Cardiac Sarcoidosis Patients

    Alice Kwon1, Audrey Liu1, Sonali Narain2, Elena Katzap3 and Galina Marder2, 1Northwell Health, Manhasset, NY, 2Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 3Northwell Health, Great NY, NY

    Background/Purpose: Cardiac sarcoidosis is one of the most common causes of mortality from sarcoidosis. In this retrospective study, we describe prescribing patterns and compare outcomes between patients treated with conventional immunosuppressive therapies…
  • Abstract Number: 1263 • ACR Convergence 2023

    Depression and Anxiety Risk Assessment in Patients with Rheumatic Diseases

    Luis Vega Sevilla1, Miguel Villarreal-Alarcon2, Diana Paola Flores-Gutierrez3, Maria Corral-Trujillo4, Ricardo Juarez4, Ivan Hernandez Galarza5, Jesus Alberto Cardenas-De la Garza6 and Dionicio A. Galarza-Delgado2, 1Hospital Universitario UANL, Garcia, Mexico, 2Hospital Universitario UANL, Monterrey, Mexico, 3Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, 4Universidad Autónoma de Nuevo León, Monterrey, Mexico, 5University Hospital, UANL, San Pedro Garza Garcia, Mexico, 6Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico

    Background/Purpose: Depression is one of the most common psychiatric comorbidities in patients with rheumatic diseases. A study has shown that almost a third of patients…
  • Abstract Number: 1332 • ACR Convergence 2023

    Patient-Reported Outcomes, Disease Activity and Safety in 798 Patients with RA Treated with Filgotinib: Up to 1-Year Interim Results from a Prospective Observational Study (FILOSOPHY)

    Gerd Burmester1, Patrick Verschueren2, Jerome AVOUAC3, Roberto F. Caporali4, Karen Bevers5, Neil Betteridge6, Thomas P.A. Debray7, Francesco De Leonardis8, Susana Romero Yuste9, Monia Zignani8 and James Galloway10, 1Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany, 2Department of Rheumatology, University Hospital Leuven and KU Leuven, Leuven, Belgium, 3Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, 4Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, 5Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 6Neil Betteridge Associates, London, United Kingdom, 7Biostatistics, Galapagos NV, Mechelen, Belgium, 8Medical Affairs, Galapagos GmbH, Basel, Switzerland, 9Complexo Hospitalario Universitario, Pontevedra, Spain, 10King's College London, London, United Kingdom

    Background/Purpose: The efficacy of filgotinib (FIL) for treating RA has been demonstrated in clinical trials. Real-world data are valuable to assess patient-reported outcomes such as…
  • Abstract Number: 0802 • ACR Convergence 2023

    Targeting Fibroblasts in Inflammatory Disease Using Engineered T Cells

    Samuel Kemble1, Christopher Mahony2, Charlotte Smith2, Joel Rurik3, Haig Aghajanian3, Jonathan Epstein3, Mark Coles4 and Adam Croft2, 1University Birmingham, Rugeley, United Kingdom, 2University of Birmingham, Birmingham, United Kingdom, 3University of Pennsylvania, Philadelphia, PA, 4University of Oxford, Oxford, United Kingdom

    Background/Purpose: Fibroblast activation protein alpha (FAPa) expressing fibroblasts orchestrate tissue inflammation and damage in rheumatoid arthritis (RA) as well as tissue immunity in primary Sjögren's…
  • Abstract Number: 1117 • ACR Convergence 2023

    Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis

    Chio Yokose1, Gregory Challener2, Baijun Zhou2, Natalie McCormick2, Sruthi Tanikella2, Kila Panchot2, Minna Kohler3, Janeth Yinh2, Yuqing Zhang4, David Bates5, James Januzzi2, Meghan Sise2, Deborah Wexler2 and Hyon K. Choi6, 1Massachusetts General Hospital, Waltham, MA, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital, Harvard Medical School, Boston, MA, 4Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, 5Brigham and Women's Hospital, Boston, MA, 6Massachusetts General Hospital and Harvard Medical School, Lexington, MA

    Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are currently indicated as second-line therapy for type 2 diabetes and are also approved for the treatment of…
  • Abstract Number: 1076 • ACR Convergence 2023

    Rituximab-Associated Hypogammaglobulinemia in Patients with Rheumatic Diseases: A Multicenter Retrospective Observational Study

    Olga Rusinovich1, Enrique Calvo-Aranda2, Claudia Maria Gomez2, Patricio Cardoso Peñafiel2, Pilar Navarro Alonso3, Miguel Cantalejo Moreira4, Alberto Diaz y Oca3, Pablo Navarro5, Maria Machattou5, Maria Alonso5, Carlota Navarro5, Carolina Merino5, Hilda Godoy6, Maria Carmen Barbadillo Mateos7, Carlos Isasi5, Maria Perez Ferro8, Jessica Polo9, Veronica Garcia10, Jose Luis Andreu-Sánchez11, Jose Campos12 and Jesus Sanz13, 1Puerta de Hierro Majadahonda University Hospital, Boadilla del Monte, Spain, 2Hospital Universitario Infanta Leonor, Madrid, Spain, 3Fuenlabrada University Hospital, Madrid, Spain, 4Hospital Universitario de Fuenlabrada, Madrid, Spain, 5Puerta de Hierro Majadahonda University Hospital, Madrid, Spain, 6Hospital Universitario Puerta de Hierro, Madrid, Spain, 7Public, Madrid, Spain, 8Hospital Universitario Rey Juan Carlos, Madrid, Spain, 9Rey Juan Carlos University Hospital, Madrid, Spain, 10Ramon y Cajal University Hospital, Madrid, Spain, 11Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, 12Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain, 13Hospital Universitario Puerta de Hierro, Majadahonda, Spain

    Background/Purpose: Rituximab (RTX) is a murine/human chimeric monoclonal antibody directed against the CD20 receptor expressed on pre-B and mature B cells. Rituximab is used effectively…
  • Abstract Number: 1071 • ACR Convergence 2023

    No Increase in Mortality in US Veterans with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors (ICIs)

    Madeline O'Sullivan1, Grant Cannon1, Brian Sauer2, Jorge Rojas Jr3, Gary Kunkel4, Jessica A Walsh5, Punyasha Roul6, Bryant England6, Ted R Mikuls7, Joshua Baker8 and Tawnie Braaten4, 1University of Utah and Salt Lake City VA, Salt Lake City, UT, 2Salt Lake City VA/University of Utah, Salt Lake City, UT, 3Puget Sound VA and University of Utah, Seattle, WA, 4University of Utah, Salt Lake City, UT, 5Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, 6University of Nebraska Medical Center, Omaha, NE, 7Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 8University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Immune checkpoint inhibitors (ICIs) are used to treat multiple cancers with increasing frequency and have led to improved survival. However, there is limited data…
  • Abstract Number: 1137 • ACR Convergence 2023

    Association Between Nailfold Videocapillaroscopy Findings and sKL-6 Levels in Patients with Idiopathic Inflammatory Myopathies–Related Interstitial Lung Disease

    Cristiana Sieiro Santos1, Jose Luis Tandaipan2, Diego Castillo2, Laura Martínez Martínez2, Helena Codes2, Luis Sainz-Comas2, Berta Paula Magallares-Lopez3, Patricia Moya2, Anais Mariscal2, Hye Sang Park2, Ana Milena Millán Arciniegas2, César Díaz-Torné2, Ana Laíz Alonso2, Sandra Ros2, Susana Fernández2, Hector Corominas4, Elvira Díez Álvarez5 and Iván Castellvi2, 1Complejo Asistencial Universitario de León, León, Spain, 2Hospital de Santa Creu i Sant Pau, Barcelona, Spain, 3Department of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, 4Hospital Universitario Sant Pau, Rheumatology, Barcelona, Spain, 5CAULE, León, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a frequent pulmonary manifestation in idiopathic inflammatory myopathies (IIM) (IIM-ILD) and considerably influences morbidity and mortality. Krebs von den…
  • Abstract Number: 1353 • ACR Convergence 2023

    Sexual Dysfunction in Women with Systemic Lupus Erythematosus: A Cross-Sectional Multicentre Study

    Maria Helena Lourenco1, Rita Torres2, Santiago Rodrigues-Manica3, Vanessa Fraga4, Ana Catarina Abreu5, Roberto Costa6, Carolina Ochôa Matos7, Beatriz Mendes8, Beatriz Samões9, Inês Silva1, Fernando Pimentel-Santos10, Manuela Costa1, Jaime Branco11 and Alexandre Sepriano12, 1Hospital Egas Moniz, Lisbon, Portugal, 2Hospital Egas Moniz, Lisboa, Portugal, 3Hospital Egas Moniz, CHLO, Lisboa, Portugal, 4Hospital Garcia de Orta, Nogueira da Regedoura, Portugal, 5Hospital Garcia de Orta, Lisboa, Portugal, 6Centro Hospitalar Lisboa Norte, Lisboa, Portugal, 7Centro Académico de Medicina de Lisboa, Lisbon, Portugal, 8Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, 9Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia, Portugal, 10NOVA Medical School; Universidade NOVA e Lisboa, Lisboa, Portugal, 11CHLO, EPE - Hospital Egas Moniz, Lisbon, Portugal, 12Leiden University Medical Centre, Portela Loures, Portugal

    Background/Purpose: Due to its multisystemic involvement, systemic lupus erythematosus (SLE) can have a significant impact on patients' quality of life (QoL). Sexual (dis)function is a…
  • Abstract Number: 1334 • ACR Convergence 2023

    Comparison of Malignancies and Serious Infections Between Etanercept Biosimilar and Bio-Originator Initiators: Population-Based Analyses

    Marina Birck1, Luck Lukusa2, Michal Abrahamowicz3, Gilles Boire4, Denis Choquette5, Walter P. Maksymowych6 and Sasha Bernatsky1, 1Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2RI-MUHC, Montreal, QC, Canada, 3McGill University, Verdun, QC, Canada, 4Université de Sherbrooke, Sherbrooke, QC, Canada, 5Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, 6University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Treatment safety, particularly malignancy and infections, is an important issue for biologics; hence, surveillance and analyses comparing biosimilar versus bio-originator use in the real…
  • Abstract Number: 1269 • ACR Convergence 2023

    The Impact of Sex, Serostatus, and Smoking on Risk for Rheumatoid Arthritis-associated Interstitial Lung Disease Subtypes

    Gregory McDermott1, Keigo Hayashi1, Pierre-Antoine Juge2, Ritu Gill1, Suzanne Byrne1, Staci Gagne1, Kathleen Vanni1, Emily Kowalski1, Grace Qian1, Katarina Bade3, Alene Saavedra1, Yumeko Kawano1, Michael Diiorio3, Taylor Wolfgang1, Edy Kim1, Paul Dellaripa3, Michael Weinblatt4, Nancy Shadick3, Tracy J. Doyle1 and Jeffrey Sparks5, 1Brigham and Women's Hospital, Boston, MA, 2Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Harvard Medical School, Waban, MA, 5Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is a heterogenous condition encompassing multiple subtypes with varying histopathology, prognosis, and potential treatment options. The most common RA-ILD…
  • Abstract Number: 1141 • ACR Convergence 2023

    COVID-19 Vaccination Status and Adverse Events Following SARS-CoV-2 Vaccine in Autoimmune Inflammatory Rheumatic Disease (AIRD) Patients: A Single Center Experience

    Vincent Luceño1, Peter Paolo Daleon1 and Sandra Navarra2, 1University of Santo Tomas Hospital, City of Manila, Philippines, 2University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines

    Background/Purpose: Autoimmune inflammatory rheumatic diseases (AIRD) were associated with an increased risk for COVID-19 infection, worse clinical outcomes, and COVID-19- related deaths. Vaccines carry the…
  • Abstract Number: 1148 • ACR Convergence 2023

    A Comparative Study of Clinical Phenotype in Relation to NOD2 Sub-genotypes in Yao Syndrome

    Ashmia Saif1, Hafsa Nomani2, Frank Hwang2, Jie Yang2 and Qingping Yao2, 1Stony Brook University Hospital, Syosset, NY, 2Stony Brook University, Stony Brook, NY

    Background/Purpose: Yao syndrome (YAOS, OMIM 617321) is formerly designated NOD2-associated autoinflammatory disease. A spectrum of NOD2 mutations have been associated with this disease. Most patients…
  • « Previous Page
  • 1
  • …
  • 253
  • 254
  • 255
  • 256
  • 257
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology